MEdPACTO

January 20, 2022 – MedPacto, Inc (KOSDAQ: 235980), a genome-based drug discovery and clinical-stage biotechnology company, announced that they had disclosed the clinical design of a combination study with Vactosertib in patients with Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI.

This upcoming release is about the investigator-initiated phase 1b clinical trial of Vactosertib in combination with 5FU/LV/Onivyde chemotherapy, which serves as an alternative treatment for patients with metastatic pancreatic ductal adenocarcinoma where first-line treatment has failed.

Pancreatic ductal adenocarcinoma (PDAC) is notorious for its low anticancer drug response as its dense fibrotic stroma is interlaced with an extracellular matrix that inhibits the access of the anticancer drugs. Surgery is viable only if the cancer cells have not spread to other adjacent organs except for the pancreas and the patient is healthy enough to go through the surgery. However, in most cases, patients get delayed diagnoses. Even in cases where the cancer is detected in the early stage when there are no symptoms, Pancreatic cancer has a high recurrence rate so chemotherapy plays a pivotal role in treatment.

5FU/LV/Onivyde chemotherapy is a standard therapy for patients with metastatic pancreatic ductal adenocarcinoma where first-line treatment has failed. The trial is to evaluate the safety of the Vactosertib in combination with 5FU/LV/Onivyde.

Prior to this, MedPacto has released the study result at the American Association for Cancer Research(AACR) showing decreased metastasis of pancreatic cancer cells and improved survival rate when using vactosertib in combination with 5FU/LV/Onivyde in the animal model. Based on this study result, MedPacto received Orphan Drug Designation(ODD) from the U.S. Food and Drug Administration(FDA).

According to MedPacto’s preclinical result released last April at AACR after addressing 5FU/LV/Onivyde for 50days, the metastasis of cancer cells decreased substantially. In addition, the combination therapy of Vactosertib and 5FU/LV/Onivyde verified its potential as a new treatment through a clinical trial in animal models showing a significantly higher survival rate of 84% compared to the controlled group(23%) and the one received current approved standard treatment(53%)

If the trial produces promising results, developing combination therapy with Vactosertib is expected to accelerate.

Meanwhile, the Abstract of the release was uploaded on an official website on Jan 18th. ASCO GI was going to be held from Jan 20th to Jan 22nd both on-site and online.